A systematic review of 31 COVID-19 patients with gastrointestinal ischemia found a 38.7% mortality rate, according to a study published in the PMC.
Prevalence and Diagnostic Imaging Findings
Gastrointestinal (GI) ischemia in COVID-19 patients often presents with abdominal pain, nausea, and vomiting, but diagnosing the condition can be delayed due to its rarity and overlap with respiratory symptoms. A 2020 systematic review of 22 studies identified 31 patients with COVID-19-related GI ischemia, with a mean age of 59 ± 12.7 years. Of these, 23 (74.2%) were male, and 7 (22.5%) were female. The study noted that mesenteric arterial or venous thromboembolism was the most common imaging finding, followed by small bowel ischemia. Nine patients (29%) had arterial compromise due to superior mesenteric thromboembolism, while six (19.3%) exhibited occlusive thrombosis of the portal system and superior mesenteric vein.
Diagnosis typically relies on contrast-enhanced computed tomography, which detected mesenteric thrombotic occlusion in 64.5% of cases. Over two-thirds of patients required laparotomy and bowel resection, but five (16.1%) were discharged, with four readmitted. At the time of reporting, 12 (38.7%) patients had died. The review highlighted that GI ischemia is a severe complication, often occurring in critically ill patients.
Mechanisms of SARS-CoV-2 Induced Thrombosis
The study linked GI ischemia in COVID-19 to macrovascular thrombosis, with 40% of patients experiencing mesenteric thrombotic occlusion. Researchers attributed this to the prothrombotic state associated with SARS-CoV-2 infection, which increases the risk of arterial and venous thromboembolism. A 2024 case report in Hematology, Transfusion and Cell Therapy analyzed 13 patients with acute mesenteric ischemia (AMI) linked to COVID-19. These patients had a median age of 56 years, with nine males and three females. AMI presented either as an initial symptom or a late complication during hospitalization, with six patients having pre-existing comorbidities such as hypertension, diabetes, and obesity.
For more on this story, see Congo Ebola Outbreak Linked to Rare Bundibugyo Variant.
The case report emphasized the need for heightened awareness among clinicians, as AMI can mimic other gastrointestinal conditions. Contrast-enhanced CT was critical for diagnosing thrombosis, with four patients showing concurrent thrombosis in other areas, including the brain and kidneys. While the review noted limited data on mesenteric thrombosis in COVID-19, it underscored the life-threatening nature of the condition, particularly in ICU settings.
Clinical Challenges in Vascular Health
The findings align with broader observations about COVID-19’s impact on vascular health. WebMD defines ischemia as reduced blood flow leading to oxygen deprivation, which can cause tissue damage. The Cleveland Clinic notes that ischemia is common in heart disease and strokes but rare in the digestive system, where it primarily affects critically ill patients. This rarity complicates early detection, as clinicians may overlook GI symptoms in favor of respiratory manifestations.
The 2020 review concluded that macrovascular thrombosis occurs in nearly half of COVID-19 patients with bowel ischemia, with mortality rates reaching 38.7% for those with radiologically confirmed mesenteric thrombosis. These outcomes highlight the urgency of recognizing thrombotic complications, particularly in high-risk groups.
This follows our earlier report, Hondius Cruise Ship Hantavirus Outbreak Rises to 12 Cases, Including Crew.
Ongoing Investigations and Clinical Guidelines
Despite these insights, gaps remain in understanding the mechanisms linking SARS-CoV-2 to GI ischemia. The 2024 case report called for further research to clarify risk factors and optimal treatment strategies. Clinicians are advised to consider thrombosis in COVID-19 patients presenting with unexplained abdominal pain, especially those with prolonged ICU stays.
As of June 2026, no updated guidelines specifically address GI ischemia in post-COVID-19 survivors, but ongoing studies continue to refine risk stratification. The integration of advanced imaging and anticoagulant therapies may improve outcomes, though more data is needed to confirm efficacy.
The interplay between viral infection and thrombosis remains a critical area of investigation, with implications for both pandemic response and long-term patient care.
Find more reporting in our Health section.
